Am J Transplant, Volume 22, Suppl 3 Archives - Page 56 of 190 - ATC Abstracts

2022 American Transplant Congress
Immunosuppressant Medications Use in Patients with Transplant Failure: A Canadian Multi-Centre Prospective Study
G. Knoll¹, M. Chassé², D. Fergusson³, A. A. House⁴, O. Johnston⁵, R. Mainra⁶, D. Baran⁷, D. Treleaven⁸, l. senecal⁹, L. Tibbles¹⁰, M. Hebert¹¹, M. Karpinski¹², T. Campbell¹³, T. Ramsay¹⁴, J. Kim¹⁵, I. Houde¹⁶, C. White¹⁷, J. Perl¹⁵, P. Karnabi¹⁸, J. Gill⁵
¹Nephrology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²University of Montreal, Montreal, QC, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴Nephrology, Western University, London, ON, Canada, ⁵Nephrology, University of British Columbia, Vancouver, BC, Canada, ⁶Nephrology, University of Saskatchewan, Saskatoon, SK, Canada, ⁷Nephrology, McGill University, Montreal, QC, Canada, ⁸Nephrology, McMaster University, Hamilton, ON, Canada, ⁹Nephrology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada, ¹⁰Nephrology, University of Calgary, Calgary, AB, Canada, ¹¹Nephrology, University of Montreal, Montreal, QC, Canada, ¹²Nephrology, University of Manitoba, Winnipeg, MB, Canada, ¹³University of Alberta, Alberta, AB, Canada, ¹⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹⁵University of Toronto, Toronto, ON, Canada, ¹⁶Laval University, Que´bec, QC, Canada, ¹⁷Queen's University, Kingston, ON, Canada, ¹⁸Ottawa Health Research Institute, Ottawa, ON, Canada
*Purpose: This prospective study determined the association of immunosuppressant medication use with the outcomes of death, hospitalized infection, rejection of the failed allograft, and panel…
2022 American Transplant Congress
Single Center Retrospective Study Examining the Safety of the New Potassium- Binders for Post-Operative Hyperkalemia in Kidney Transplant Recipients
S. Kapoor¹, A. Campbell², Y. Azzi¹, L. E. Liriano-Ward³, T. Shertel⁴, W. Xiao⁵, D. U. Nnani⁶, S. Farghaly¹, S. Yun⁷, E. Akalin¹, M. Ajaimy¹
¹Einstein-Montefiore Transplant Center, Bronx, NY, ²Montefiore Medical Center, Bronx, NY, ³Transplant, Montefiore Medical Center, Bronx, NY, ⁴-, -, AL, ⁵Albert Einstein College of Medicine, Folsom, CA, ⁶Pharmacy, Montefiore Medical Center, Bronx, NY, ⁷Montefiore Medical Center, New York, NY
*Purpose: We aimed to evaluate the safety and efficacy of two potassium-binders (Patiromer and Sodium Zirconium Cyclosilicate (SZC) in early post-transplant hyperkalemia treatment of kidney…
2022 American Transplant Congress
Survival Benefit of Early Kidney Transplantation in Infants and Toddlers
S. J. Kizilbash¹, M. Evans², D. Vock², B. Chavers³
¹University of MInnesota, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN, ³Division of Nephrology, Minneapolis, MN
*Purpose: The 1-year mortality in children with end-stage kidney disease (ESKD) has been the highest among infants and toddlers. The objective of this study was…
2022 American Transplant Congress
Effect of Schisandra Sphenanthera Extract on Pharmacokinetics of Tacrolimus in Pediatric Renal Transplant Recipients
J. Jiang¹, H. Zhang¹, X. Su¹, S. Wu¹, Y. Chen², W. Chen², J. Li², C. Wu², L. Yang², L. Liu², C. Wang²
¹Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*Purpose: Wuzhi tablet (Schisandra sphenanthera extract) is a promising tacrolimus-sparing agent in adult renal transplant recipients, while its effect in pediatric recipients remains unclear. The…
2022 American Transplant Congress
Revision Ureteroneocystostomy in Pediatric Renal Transplant Patients for Symptomatic Vesicoureteral Reflux and Its Effect on Recurrent Hospitalizations
P. Campbell¹, M. Christman¹, S. Marietti², E. Ingulli²
¹Naval Medical Center San Diego, San Diego, CA, ²UCSD Rady Children's Hospital, San Diego, CA
*Purpose: To evaluate the effect of revision ureteroneocystostomy on pediatric renal transplant patients with symptomatic vesicoureteral reflux (VUR) in reducing hospitalizations and recurrent urinary tract…
2022 American Transplant Congress
Glucose Variability in Kidney Transplantation: Pre-Transplant and Post-Transplant Continuous Glucose Monitoring
E. Jo¹, A. Han², S. Min², J. Ha³, H. Lee⁴, A. Cho⁵
¹Surgery, Seoul National University Hospital, Seoul, Korea, Republic of, ²Seoul National University College of Medicine, Seoul, Korea, Republic of, ³Seoul Nat'l Univ. College of Medicine, Seoul, Korea, Republic of, ⁴Seoul National University Hospital, Seoul, Korea, Republic of, ⁵Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of
*Purpose: Continuous glucose monitoring (CGM) provides a 24-hour view of glucose values and information on glycemic variability and additional indices such as the glucose management…
2022 American Transplant Congress
BiomarkeR Initiative to Advance Transplantation OutcomEs in Children (BRITE-c) Analysis
M. E. Seifert¹, L. Sheward², A. Kho², N. Rodig², V. Dharnidharka³, M. Diehl², R. B. Mannon⁴, O. Bestard⁵, T. Blydt-Hansen⁶, D. M. Briscoe²
¹University of Alabama, Birmingham, AL, ²Boston Children's Hospital, Boston, MA, ³St Louis Children's Hospital, St Louis, MO, ⁴University of Nebraska, Omaha, NE, ⁵Bellvitge University Hospital, Barcelona, Spain, ⁶BC Childrens, Vancouver, BC, Canada
*Purpose: Recent studies indicate that 25-36% of clinically stable pediatric renal transplant recipients will have subclinical rejection detected on surveillance biopsy. These findings highlight a…
2022 American Transplant Congress
Longevity Matching for Living Donor Renal Transplantation
S. Karhadkar¹, J. Dawes¹, K. Wirshup¹, J. Kolansky¹, A. Gregor¹, A. Diamond², A. DiCarlo¹
¹Temple University Hospital, Philadelphia, PA, ²-, Garnet Valley, PA
*Purpose: Living donor kidney transplantation (LDKT) continues to become a more prevalent treatment method for ESRD and is known to increase both organ availability and…
2022 American Transplant Congress
Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients
T. S. Mahmoud¹, J. Yagan¹, A. Hasan², O. Gheith¹, M. Mostafa¹, S. Rida¹, N. El-Serwy¹, M. Shaker¹, M. Khalid¹, P. Nair¹, T. Alotaibi¹
¹Nephrology, Organ Transplant Center, Kuwait, Kuwait, ²Immunometabolism, Dasman Diabetes Center, Kuwait, Kuwait
*Purpose: The impact of the new glucose lowering therapies, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA), on managing patients with type…
2022 American Transplant Congress
Six-Month Outcomes Among Lung Transplant Patients with COVID-19
L. D. Mahan, J. Rose, M. Mohanka, A. Banga
UT Southwestern Medical Center, Dallas, TX
*Purpose: There is limited data on the outcomes beyond the acute illness among lung transplant (LT) patients with Coronavirus disease 2019 (COVID-19). The current study…